BioSpace News Archive

Histogen Inc., a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock.

Oracle Corporation announced that all required antitrust approvals have been obtained for its proposed acquisition of Cerner, including European Commission clearance.

Karyopharm Therapeutics Inc. announced that the Company approved the grant of stock options to purchase an aggregate of 136,700 shares of Karyopharm’s common stock and an aggregate of 90,700 restricted stock units to 18 newly-hired employees.

Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President, and Chief Executive Officer, will present at the Jefferies Healthcare Conference in New York on Wednesday, June 8 at 9:30 a.m. ET.

Spruce Biosciences, Inc. announced that company management will participate in two upcoming investor conferences taking place in June.

Paratek Pharmaceuticals, Inc. announced that on May 31, 2022, the Company granted stock options and restricted stock units to twelve new employees of the Company.

SciSparc Ltd. closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $10 million, before deducting fees to the placement agent and other expenses payable by the Company.

Jazz Pharmaceuticals plc announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST in New York.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500).

Renovacor, Inc. announced the publication of the results of a preclinical study demonstrating cardiac transduction with low-doses of REN-001 delivered via retrograde coronary sinus infusion in healthy Yucatan pigs.